Evaluating HBVZ10-based therapied for cccdna clearance: virological foundation and synergistic combinations
Active Definitive Contract Awarded Last action
- Contract number
- 75N93025C00023
- Awardee
-
Hbvtech, L.l.c UEI WEXNYHY4EZB5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $606,178
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20251 · Posted Jul 18, 2024
- Contract value 23% obligated
-
- $606,178.00 Current, with exercised options
- $2,656,170.00 Potential, with all options
- Completion date 25% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Germantown, MD, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $606,178 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $2.656 million definitive contract to Hbvtech, L.l.c on August 1, 2025, under a total small business set-away, for evaluating HBVZ10-based therapies for hepatitis B virus covalently closed circular DNA (cccDNA) clearance with virological foundation and synergistic combinations research.
Hbvtech is a minority-owned small disadvantaged business. The contract carries firm fixed price terms and a ceiling value of $2.656 million. Place of performance is Germantown, MD. The contract's ultimate completion date is July 31, 2030.
The originating Small Business Innovation Research (SBIR) solicitation, posted July 18, 2024, with due date October 18, 2024, sought proposals from small business concerns across a range of NIH institutes and CDC centers for research topics including drug development, diagnostics, and medical devices. The SBIR program supports technological innovation, strengthens the role of small businesses in federal research, and increases commercialization of innovations. Eligible small businesses must meet SBIR size standards of no more than 500 employees with majority ownership by U.S. citizens or permanent resident aliens.
Quick answers
Who was awarded contract 75N93025C00023?
75N93025C00023 was awarded to Hbvtech, L.l.c by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 27, 2025.
How much is contract 75N93025C00023 worth?
The government has obligated $606,178 on 75N93025C00023. Its potential value, with all options, is $2,656,170.
Was contract 75N93025C00023 competed?
The extent of competition for 75N93025C00023 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award